Denne side blev automatisk oversat, og nøjagtigheden af ​​oversættelsen er ikke garanteret. Der henvises til engelsk version for en kildetekst.

A Clinical Trial to Evaluate the Effects of the Synbiotic Dual Cap® on Gastrointestinal Comfort in Adults Initiating GLP-1 or Dual-Incretin Therapy for Weight Loss.

12. november 2026 opdateret af: Epetome

This is a decentralized, single-group, open-label clinical trial evaluating the effects of the Synbiotic Dual Cap® in 40 adults who have initiated GLP-1 or dual-incretin therapy within the preceding 60 days and who are experiencing at least one associated gastrointestinal symptom. All participants will receive the Synbiotic Dual Cap® (1 capsule daily, taken in the morning without food) alongside their existing GLP-1 medication for 12 consecutive weeks.

Participants will complete study-specific questionnaires at four assessment timepoints: Baseline, Week 4, Week 8, and Week 12. No placebo control arm is included; all efficacy comparisons are within-subject against Baseline values. The study is conducted entirely remotely via the Citruslabs digital platform, with the study product shipped directly to participants' homes.

Studieoversigt

Undersøgelsestype

Interventionel

Tilmelding (Anslået)

40

Fase

  • Ikke anvendelig

Kontakter og lokationer

Dette afsnit indeholder kontaktoplysninger for dem, der udfører undersøgelsen, og oplysninger om, hvor denne undersøgelse udføres.

Studiekontakt

Studiesteder

    • Nevada
      • Las Vegas, Nevada, Forenede Stater, 89101
        • Citruslabs

Deltagelseskriterier

Forskere leder efter personer, der passer til en bestemt beskrivelse, kaldet berettigelseskriterier. Nogle eksempler på disse kriterier er en persons generelle helbredstilstand eller tidligere behandlinger.

Berettigelseskriterier

Aldre berettiget til at studere

18 år til 65 år (Voksen, Ældre voksen)

Tager imod sunde frivillige

Ingen

Køn, der er berettiget til at studere

Alle

Beskrivelse

Inclusion Criteria:

  • Adults aged 18-65 years.
  • Have initiated a GLP-1 receptor agonist or dual-incretin medication for weight loss (including but not limited to semaglutide, tirzepatide, or liraglutide) within the last 60 days prior to the date of enrollment.
  • Self-reported experience of at least one gastrointestinal symptom associated with GLP-1 initiation, including nausea, bloating, constipation, diarrhea, or general digestive discomfort, at the time of screening.
  • Currently on a stable GLP-1 dose as directed by their prescribing physician.
  • Willing to take one Synbiotic Dual Cap® daily for 12 consecutive weeks alongside their existing GLP-1 medication and complete all questionnaire assessments at Baseline, Week 4, Week 8, and Week 12.
  • Willing and able to provide informed consent prior to enrollment.
  • In good general health (GLP-1 use and associated weight-related conditions do not disqualify a participant).
  • Reside in the United States.

Exclusion Criteria:

  • Currently pregnant or breastfeeding (or planning to become pregnant during the study period).
  • Currently taking other fibre, probiotic, prebiotic, or synbiotic supplements that cannot be discontinued for the study period.
  • Diagnosed with a chronic gastrointestinal condition requiring active prescription medical management - including Crohn's disease, ulcerative colitis, coeliac disease, GERD, or gastroparesis - that would independently confound GI symptom endpoints.
  • Use of antibiotics or prescription gastrointestinal medications within the past 30 days prior to enrollment, or intentions to use these medications during the study period.
  • Anyone currently participating or planning to participate in another research study during the study period.
  • Currently receiving immunosuppressant therapy of any kind.
  • Currently undergoing cancer treatment or have had a serious illness requiring hospitalization in the last three months.
  • Reside in Hawaii.
  • Known allergy or hypersensitivity to any ingredient in the Synbiotic Dual Cap®.

Studieplan

Dette afsnit indeholder detaljer om studieplanen, herunder hvordan undersøgelsen er designet, og hvad undersøgelsen måler.

Hvordan er undersøgelsen tilrettelagt?

Design detaljer

  • Primært formål: Behandling
  • Tildeling: N/A
  • Interventionel model: Enkelt gruppeopgave
  • Maskning: Ingen (Åben etiket)

Våben og indgreb

Deltagergruppe / Arm
Intervention / Behandling
Eksperimentel: Synbiotic Dual Cap® Arm

Participants will take 1 capsule each morning, without food and without a hot drink, for 12 consecutive weeks alongside their existing GLP-1 medication.

Hvad måler undersøgelsen?

Primære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Change in Overall Gastrointestinal Comfort
Tidsramme: Baseline to Week 12

Within-subject change from Baseline in overall gastrointestinal comfort severity, assessed using study-specific questionnaires

Baseline to Week 12
Change in Bowel Regularity
Tidsramme: Baseline to Week 12

Within-subject change from Baseline in bowel regularity, assessed using study-specific questionnaires

Baseline to Week 12
Change in Bloating
Tidsramme: Baseline to Week 12

Within-subject change from Baseline in bloating severity and frequency, assessed using study-specific questionnaires

Baseline to Week 12
Change in Constipation
Tidsramme: Baseline to Week 12

Within-subject change from Baseline in constipation severity and frequency, assessed using study-specific questionnaires

Baseline to Week 12
Change in Diarrhea
Tidsramme: Baseline to Week 12

Within-subject change from Baseline in diarrhea severity and frequency, assessed using study-specific questionnaires

Baseline to Week 12
Change in Nausea
Tidsramme: Baseline to Week 12

Within-subject change from Baseline in nausea severity and frequency, assessed using study-specific questionnaires

Baseline to Week 12
Change in Post-Meal Fullness Comfort
Tidsramme: Baseline to Week 12

Within-subject change from Baseline in comfort with post-meal fullness, assessed using study-specific questionnaires

Baseline to Week 12

Sekundære resultatmål

Resultatmål
Foranstaltningsbeskrivelse
Tidsramme
Participant Perception of Effect on Overall Gastrointestinal Comfort
Tidsramme: Week 4, Week 8, and Week 12

Participants' self-reported perception of the product's tolerability and effect on overall gastrointestinal comfort, assessed using questionnaires

Week 4, Week 8, and Week 12
Participant Perception of Effect on Bowel Regularity
Tidsramme: Week 4, Week 8, and Week 12

Participants' self-reported perception of the product's tolerability and effect on bowel regularity, assessed using questionnaires

Week 4, Week 8, and Week 12
Participant Perception of Effect on Bloating
Tidsramme: Week 4, Week 8, and Week 12

Participants' self-reported perception of the product's tolerability and effect on bloating, assessed using questionnaires

Week 4, Week 8, and Week 12
Participant Perception of Effect on Constipation
Tidsramme: Week 4, Week 8, and Week 12

Participants' self-reported perception of the product's tolerability and effect on constipation, assessed using questionnaires

Week 4, Week 8, and Week 12
Participant Perception of Effect on Diarrhea
Tidsramme: Week 4, Week 8, and Week 12

Participants' self-reported perception of the product's tolerability and effect on diarrhea, assessed using questionnaires

Week 4, Week 8, and Week 12
Participant Perception of Effect on Nausea
Tidsramme: Week 4, Week 8, and Week 12

Participants' self-reported perception of the product's tolerability and effect on nausea, assessed using questionnaires

Week 4, Week 8, and Week 12
Participant Perception of Effect on Post-Meal Fullness Comfort
Tidsramme: Week 4, Week 8, and Week 12

Participants' self-reported perception of the product's tolerability and effect on post-meal fullness comfort, assessed using questionnaires

Week 4, Week 8, and Week 12

Samarbejdspartnere og efterforskere

Det er her, du vil finde personer og organisationer, der er involveret i denne undersøgelse.

Sponsor

Samarbejdspartnere

Datoer for undersøgelser

Disse datoer sporer fremskridtene for indsendelser af undersøgelsesrekord og resumeresultater til ClinicalTrials.gov. Studieregistreringer og rapporterede resultater gennemgås af National Library of Medicine (NLM) for at sikre, at de opfylder specifikke kvalitetskontrolstandarder, før de offentliggøres på den offentlige hjemmeside.

Studer store datoer

Studiestart (Anslået)

1. november 2026

Primær færdiggørelse (Anslået)

1. februar 2027

Studieafslutning (Anslået)

1. februar 2027

Datoer for studieregistrering

Først indsendt

12. november 2026

Først indsendt, der opfyldte QC-kriterier

12. november 2026

Først opslået (Faktiske)

18. november 2026

Opdateringer af undersøgelsesjournaler

Sidste opdatering sendt (Faktiske)

18. november 2026

Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier

12. november 2026

Sidst verificeret

1. november 2026

Mere information

Begreber relateret til denne undersøgelse

Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter

Studerer et amerikansk FDA-reguleret lægemiddelprodukt

Ingen

Studerer et amerikansk FDA-reguleret enhedsprodukt

Ingen

Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .

Abonner